← Leaderboards
Kenneth Hillan
Achaogen, Inc.
$5,316,115
Attributed
$5,316,115
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2015–17$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
Funding mix
By agency
NIH$5,316,115 · 1
By mechanism
N01$5,316,115 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalTherapeutic DevelopmentSeriesSmall MoleculeCommunicable DiseasesDrug CandidateBurkholderia PseudomalleiFutureGram-Negative BacteriaInfectious Disease TreatmentIn VitroIn VivoLeadToxic EffectPharmaceutical ChemistryYersinia PestisBurkholderia MalleiFrancisella TularensisMulti-Drug ResistanceStagingBacterial Drug ResistanceClinical DevelopmentPseudomonas Aeruginosa
Grant awards (3)
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$882,497
N01 · FY2017 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$2,933,817
N01 · FY2016 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,499,801
N01 · FY2015 · AI · contact PI